InvestorsHub Logo
Followers 24
Posts 2277
Boards Moderated 0
Alias Born 03/18/2013

Re: raistthemage post# 160976

Monday, 11/19/2018 12:45:54 PM

Monday, November 19, 2018 12:45:54 PM

Post# of 428701
Raisttheimage; Amarin Valuation, Be careful with assumptions;

"Almost everyone on Statins will be on Vascepa?" Not quite, there's no study to prove-it yet, but some posters have posted (Trial of 1) that the combination of a Statin & Vascepa have caused a "Plaque Regression?" So, the jury is still out unless someone has done a study to prove this anomaly either way?

Your numbers are in the ballpark; 30 Million (Just USA)? Not counting Europe, Middle East or Asia (Generic Epadel).

Amarin's Margin% is roughly 70%-75% (why 60%?)

Annual script based on "my own experience" $2500 (4 x $630 = $2520)

Agree that $45 PPS is too low, using your numbers (30 million scripts), assuming no dilution or debt financing

($2520*30M*.70) = 52.9B/(373M shares) = 141.88/ share - G&A ($20 / share)

So, $120 per share approx. All depends on time to get to 30M scripts per year

Amarin is very close to break even (Cash Flow positive @ approx. 32k scripts per week).

Be nice if HD Gabor could weigh in here..... :D)
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News